highly potent nanobodies

our platform

Our single-domain antibodies are of superior specificity,  low picomolar target-binding, and high thermal stability. They are selected by phage display from camelid immune libraries, and are suitable for large-scale production in E. coli or yeast (Pichia pastoris).

Our proprietary technology is being used to develop highly potent preventive and therapeutic medications against a variety of infectious diseases, including COVID-19, MRSA, Tuberculosis and Malaria, and as well as in immuno-oncology.

VicuTec Biologicals GmbH is working in concert with the Max Planck Foundation, the Max Planck Society, the Max Planck Institute for Biophysical Chemistry, and the University Medical Center Göttingen. This cooperation is being supported by kENUP Foundation.